In this Medscape commentary, Dr. Scott Kopetz of MD Anderson unpacks the rising role of ctDNA in colorectal cancer. Unlike traditional risk factors, ctDNA offers a real-time snapshot of tumor biology with powerful prognostic value. From guiding adjuvant therapy decisions in stage 2 and 3 disease to detecting recurrence months before imaging, the test is reshaping how oncologists think about surveillance and trial design. With sensitivity still evolving and novel therapies on the horizon, is ctDNA about to become the new backbone of CRC management?
Trending
- 5 Top Tips for Colonoscopy (GI & Endoscopy News)
- Scientists uncover gut signals that may improve early cancer detection (Earth.com)
- The AGA Research Foundation awards $2.9 million in digestive health research funding (EurekAlert!)
- The GI hospitalist: A practice-changing health care opportunity (MDedge)
- Virtual Multidisciplinary GI Care Improves Outcomes, Reduces Costs (Gastroenterology Advisor)
- Validation of the American Society for Gastrointestinal Endoscopy’s Complexity Grading System for Endoscopic Procedures (Clinical and Translational Gastroenterology )
- A Randomized Trial of Rifaximin vs Low FODMAP Diet for Symptom Outcomes and Microbiome Changes in Irritable Bowel Syndrome (Clinical GI & Hepatology)
- Aspirin Unlikely to Cut Colorectal Cancer Incidence (Medscape)
